SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorder therapies, has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD). The trial is being conducted at the Soroka Medical Center in Israel and involves a double-blind, randomized, and placebo-controlled study to compare the efficacy of SCI-210 against standard CBD monotherapy in managing ASD symptoms. SciSparc plans to enroll 60 subjects aged between five and 18 over a 20-week period. The company aims to commercialize SCI-210 in Israel first, followed by other countries, pending regulatory approvals. The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement...Show More

SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorder therapies, has announced the enrollment and dosing of the first five patients in its clinical trial for SCI-210, a treatment for autism spectrum disorder (ASD). The trial is being conducted at the Soroka Medical Center in Israel and involves a double-blind, randomized, and placebo-controlled study to compare the efficacy of SCI-210 against standard CBD monotherapy in managing ASD symptoms. SciSparc plans to enroll 60 subjects aged between five and 18 over a 20-week period. The company aims to commercialize SCI-210 in Israel first, followed by other countries, pending regulatory approvals. The trial's primary efficacy metrics include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement, and the effective therapeutic dose. The trial design was advised by the National Autism Research Center in Israel. SciSparc's CEO, Oz Adler, expressed optimism about the trial's progress and its potential to contribute new scientific data for the treatment of ASD. SciSparc is also involved in drug development programs for other conditions, including Tourette Syndrome, Alzheimer's disease, pain, and status epilepticus, with a focus on cannabinoid pharmaceuticals.